السبت، 20 يونيو 2020

Remdesivir

Remdesivir

Remdesivir is a broad-spectrum antiviral medication developed by the biopharmaceutical company Gilead Sciences.  It is administered via injection into a vein.  As of 2020, remdesivir is being tested as a specific treatment for COVID-19, and has been authorized for emergency use in the US, India,  Singapore,  and approved for use in Japan for people with severe symptoms. It also received approval in the UK in May 2020, however, it was going to be rationed due to limited supply  It may shorten the time it takes to recover from the infection. 

Side effects may include liver inflammation and an infusion-related reaction with nausea, low blood pressure, and sweating. It is a prodrug that is converted in the body into GS-441524, a ribonucleotide analog.

Earlier studies found antiviral activity against several RNA viruses including SARS coronavirus and MERS coronavirus, but it is not approved for any indication.  Remdesivir was originally developed to treat hepatitis C  and was then tested against Ebola virus disease and Marburg virus disease, but was ineffective for all of these viral infections
The most common adverse effects in studies of remdesivir for COVID‑19 include respiratory failure and organ impairment, including low albumin, low potassium, low count of red blood cells, low count of platelets that help with clotting, and yellow discoloration of the skin.    Other reported side effects include gastrointestinal distress, elevated transaminase levels in the blood (liver enzymes), and infusion site reactions. 

Other possible side effects of remdesivir include:

Infusion‐related reactions. Infusion‐related reactions have been seen during a remdesivir infusion or around the time remdesivir was given.  Signs and symptoms of infusion‐related reactions may include: low blood pressure, nausea, vomiting, sweating, and shivering. 
Increases in levels of liver enzymes, seen in abnormal liver blood tests. Increases in levels of liver enzymes have been seen in people who have received remdesivir, which may be a sign of inflammation or damage to cells in the liver
Reference

ليست هناك تعليقات:

إرسال تعليق

زياد علي

زياد علي محمد